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Tumors require blood supply and, to overcome this restriction, induce angiogene-
sis. Vascular endothelial growth factor (VEGF) plays an important role in this pro-
cess, which explains the great number of antiangiogenic therapies targeting
VEGF. The research and development of targeted therapy has led to the approval
of bevacizumab, a humanized anti-VEGF monoclonal antibody (mAb), in clinical
settings. However, side effects have been reported, usually as a consequence of
bolus-dose administration of the antibody. This limitation could be circumvented
through the use of anti-idiotype (Id) antibodies. In the present study, we evalu-
ated the efficacy of an active VEGF-binding immune response generated by an
anti-bevacizumab idiotype mAb, 10.D7. The 10.D7 anti-Id mAb vaccination led to
detectable levels of VEGF-binding anti-anti-Id antibodies. In order to examine
whether this humoral immune response could have implications for tumor devel-
opment, 10.D7-immunized mice were challenged with B16-F10 tumor cells. Mice
immunized with 10.D7 anti-Id mAb revealed reduced tumor growth when com-
pared to control groups. Histological analyses of tumor sections from 10.D7-
immunized mice showed increased necrotic areas, decreased CD31-positive vascu-
lar density and reduced CD68-positive cell infiltration. Our results encourage
further therapeutic studies, particularly if one considers that the anti-Id therapeu-
tic vaccination maintains stable levels of VEGF-binding antibodies, which might
be useful in the control of tumor relapse.
L ike any tissue, tumors require blood supply.
(1) The vascular
endothelial growth factor (VEGF) is a key angiogenic factor
secreted by several tumors, at least in their initial stages.(2) Thus,
therapies targeting angiogenesis have a place in treating human
cancer. A humanized anti-VEGF monoclonal antibody (mAb),
bevacizumab, has been approved for use, with other drugs, for
certain tumors.(3,4) However, clinical studies show that the use of
bevacizumab is associated with some side effects, such as gas-
trointestinal bleeding, thrombotic events, epistaxis and hyperten-
sive episodes.(3,5) These complications are related to the weekly
or the 2-week administrations of antibody in massive doses,
which often prevent continuing treatment.(3)
Taking into account our experience with anti-idiotype (anti-
Id) antibodies,(6,7) we considered that the idiotype network
approach could circumvent the need for administration of high
doses of anti-VEGF antibodies. In contrast to this, therapeutic
vaccination with an anti-Id mAb stimulates an active immune
response, usually of low but sustained intensity.
Therefore, the aim of the present study was to prove the
concept that it is possible to obtain a VEGF mimic anti-Id
antibody. For this, we examined whether the anti-Id mAb
immunization triggers a VEGF-binding antibody response able
to inhibit angiogenesis and, thereby, interfere with the tumor
growth.
Materials and Methods
Hybridoma, HUVEC and B16-F10 melanoma cells were cul-
tured as described previously.(8) Antibody generation was
obtained by hybridoma technology(6) and VEGF-binding anti-
body detection by ELISA.(9) Detailed procedures are described
in Data S1.
Results
Generation of anti-bevacizumab idiotype monoclonal antibody,
10.D7. To generate an anti-bevacizumab idiotype antibody,
four BALB ⁄C mice were immunized with KLH-conjugated
bevacizumab. Screening was based on the inhibition of
biotinylated bevacizumab binding to hVEGF in the presence
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of immune serum. After limiting dilution cloning, stable anti-
bevacizumab idiotype-secreting hybridoma clone 10.D7 was
selected and the secreted antibody was determined to be an
IgG1 isotype.
Therapeutic vaccination with 10.D7 anti-idiotype monoclonal
antibody impairs tumor growth and angiogenesis. We used the
B16-10 tumor model to examine the therapeutic potential of
our proposed anti-Id mAb vaccination. Mice were challenged
with B16-F10 cells on the 10th day after boost immunization,
according to the experimental schedule shown in Figure 1a.
Vaccination with 10.D7 anti-Id mAb resulted in significantly
reduced tumor growth, compared to the adjuvant and isotype
immunized control groups (P < 0.05; one-way ANOVA). Tumor
growth curves are plotted in Figure 1b.
The presence of detectable levels of hVEGF-binding anti-
bodies in serum samples from 10.D7 anti-Id mAb-immunized
mice immediately before B16-F10 cell injection was verified
by ELISA (Fig. 1c). It is important to observe here that such
immune sera recognize not only hVEGF but also the murine
form of this factor. Bevacizumab, in comparison, could bind
only to hVEGF, as expected (Fig. 2).
Histological analyses of HE-stained sections revealed an
increase of necrotic area in tumors from mice immunized
with 10.D7 anti-Id mAb: the mean percentage of tumor
necrotic area was approximately fivefold higher than that
observed in the control groups (P < 0.05; one-way ANOVA).
Representative HE-stained sections and the respective
necrosis quantification are shown in Figure 3a. This result
was accompanied by a decreased CD31-positive vascular
network in subcutaneous tumors excised from the 10.D7
anti-Id mAb-immunized group, compared to controls
(P < 0.05; one-way ANOVA; Fig. 3b). In addition, a reduced
number of CD68-positive cells were observed in tumors from
10.D7 mAb-immunized mice (P < 0.05, one-way ANOVA)
(Fig. 3c).
Furthermore, such angiogenic inhibition was also observed
by in vitro tubulogenesis assay. As shown in Figure 4,
HUVEC incubation with sera obtained after 10.D7 anti-Id
mAb immunization gave a reduced and poorly organized capil-
lary-like plexus, compared with the serum controls (P < 0.05;
one-way ANOVA).
Discussion
The use of anti-Id antibodies acting as an internal image of
tumor-expressing antigens on vaccination settings offers the
opportunity to overcome tolerance to auto-antigens(10) and to
control tumor progression,(11,12) with some studies already in
clinical development (Table S1). Herein, we show the effec-
tiveness of an anti-bevacizumab idiotype antibody in generat-
ing an active VEGF-binding immune response. As far as we
know, this is the first time that an anti-Id approach has been
used to inhibit angiogenesis.
The B16-F10 tumor model was chosen to investigate the
therapeutic viability of our anti-bevacizumab idiotype mAb
vaccination approach. Despite clinical studies pointing to the
non-responsiveness of melanomas to VEGF-targeting thera-
pies,(13,14) the previous reported impairments of B16-F10 solid
tumor growth and vascular density by anti-VEGF antibod-
ies(15,16) provide a rationale for the use of this experimental
mouse model.
The effectiveness of the studied anti-Id mAb vaccination
was revealed by the detection of serum VEGF-binding anti-
bodies, in B16-F10-challenged animals, leading to tumors with
reduced size and higher necrotic areas, compared to those
obtained in the control groups. The antiangiogenic activity
obtained by anti-Id vaccination was evidenced by the signifi-
cantly lower CD31-positive tumor vascular area, as well as by
the hampered in vitro formation of tube-like structures of
HUVEC, known to secrete VEGF.(17) These results are in
(a)
(b) (c)
Fig. 1. 10.D7 anti-idiotype (anti-Id) antibody
vaccination compromises tumor growth. (a)
Experimental design. (b) B16-F10 tumor growth
curves. Mice were immunized with 10.D7 anti-Id
monoclonal antibody (mAb) (or controls). (c) ELISA
detection of VEGF-binding antibodies in 1:100-
diluted serum samples from mice 10 days after
immunization boost. Adjuvant control, n = 6;
isotype control mAb-immunized, n = 8; 10.D7 anti-
Id mAb-immunized group, n = 8. Data are
representative of three independent experiments.
Mean  SD. *P < 0.05; one-way ANOVA ⁄ Bonferroni’s
post-test.
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agreement with previous reports stating that VEGF inhibition,
mainly in the early stages of tumor growth, impairs tumor
angiogenesis and its further progression.(16,18)
It is already known that even though bevacizumab seems
to interact with degraded products of murine VEGF,(19) it
fails in inhibiting mVEGF-induced activity and in displaying
any effect on murine tumor growth.(20) Despite this, sera
from mice immunized with 10.D7 anti-bevacizumab idiotype
antibody recognize both murine and human VEGF, which
makes it reasonable to assume that the in vivo data pre-
sented here might be, at least in part, the result of mVEGF
immunoneutralization by VEGF-binding antibody serum
content.
Given that VEGF acts in several processes in the tumor
microenvironment, mechanisms other than impairing tumor
angiogenesis might be behind our therapeutic findings. Of
note, it is known that VEGF blocking strategies led to reduced
recruitment and retention of circulating myeloid cells, like
monocytes, to the perivascular area,(21) as well as to enhanced
activation of dendritic cells.(22) In fact, analyses of tumors
from 10.D7 mAb-immunized mice pointed in the same direc-
tion. In addition, Fc-mediated mechanisms, such as comple-
ment- or antibody dependent cell-mediated cytotoxicities,
might contribute to the reduced tumor growth observed.
Overall, mice immunization with an anti-bevacizumab idio-
type antibody was effective in eliciting VEGF-binding humoral
IgG antibodies capable of impairing vascular density and
tumor growth. The proposed vaccination should be considered
as an antiangiogenic therapeutic strategy for controlling the
progression of VEGF-dependent tumors, including post-surgi-
cal resection relapse scenarios, where VEGF plays an impor-
tant role.(23,24)
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Fig. 2. Serum from 10.D7 anti-idiotype (anti-Id) antibody-immunized
mice recognizes murine and human vascular endothelial growth
factor (VEGF). VEGF-binding evaluated by ELISA.
Fig. 3. 10.D7 anti-idiotype (anti-Id) monoclonal antibody (mAb) vac-
cination increases necrosis and reduces CD31-positive vessel area and
CD68-positive cells in a murine tumor model. (a) Representative HE-
stained B16-F10 tumor sections from the group immunized with
10.D7 anti-Id mAb (or controls). Graph shows quantification of %
necrosis area. Adjuvant control, n = 6; isotypic control mAb-immu-
nized, n = 7; 10.D7 anti-Id mAb-immunized group, n = 5. (b) Repre-
sentative images of tumor sections immunolabeled for CD31. Graph
shows quantification of %CD31-positive vessels per tumor section
area. CD31, green; DAPI, blue. Adjuvant control, n = 5; isotypic con-
trol mAb-immunized, n = 7; 10.D7 anti-Id mAb-immunized group,
n = 7. (c) Representative images of tumor sections immunolabeled
for CD68. Graph shows quantification of %CD68-positive cells per
tumor section area. CD68, green; DAPI, blue. Adjuvant control, n = 5;
isotypic control mAb-immunized, n = 7; 10.D7 anti-Id mAb-immu-
nized group, n = 7. *P < 0.05; one-way ANOVA ⁄ Bonferroni’s post-test,
related to controls.
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